Raymond Hohl
Raymond Hohl
Penn State Cancer Institute
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung, RE Albright, J Olson, R Fredericks, K Fink, MD Prados, ...
British journal of cancer 83 (5), 588-593, 2000
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
JE Karp, JE Lancet, SH Kaufmann, DW End, JJ Wright, K Bol, I Horak, ...
Blood, The Journal of the American Society of Hematology 97 (11), 3361-3369, 2001
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
A Thibault, D Samid, AC Tompkins, WD Figg, MR Cooper, RJ Hohl, ...
Clinical cancer research: an official journal of the American Association …, 1996
Isoprenoids: remarkable diversity of form and function
SA Holstein, RJ Hohl
Lipids 39 (4), 293-309, 2004
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301
AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ...
Journal of Clinical Oncology 27 (11), 1800, 2009
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565
AP Venook, MJ Egorin, GL Rosner, D Hollis, S Mani, M Hawkins, J Byrd, ...
Journal of clinical oncology 18 (14), 2780-2787, 2000
Anti-cancer therapy: targeting the mevalonate pathway
KM Swanson, RJ Hohl
Current cancer drug targets 6 (1), 15-37, 2006
Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation
CK Lee, RD Gingrich, RJ Hohl, KA Ajram
Bone marrow transplantation 16 (1), 175-182, 1995
Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent
J Kang, V Kumar, D Yang, PR Chowdhury, RJ Hohl
European journal of pharmaceutical sciences 15 (2), 163-170, 2002
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A Gronchi, BN Bui, S Bonvalot, S Pilotti, S Ferrari, P Hohenberger, ...
Annals of oncology 23 (3), 771-776, 2012
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473
CP Burns, S Halabi, GH Clamon, V Hars, BA Wagner, RJ Hohl, E Lester, ...
Clinical Cancer Research 5 (12), 3942-3947, 1999
Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia: A Cancer and Leukemia Group B study
CP Burns, S Halabi, G Clamon, E Kaplan, RJ Hohl, JN Atkins, ...
Cancer 101 (2), 370-378, 2004
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
AP Venook, MJ Egorin, GL Rosner, TD Brown, TM Jahan, G Batist, R Hohl, ...
Journal of clinical oncology 16 (5), 1811-1819, 1998
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase
SA Holstein, DM Cermak, DF Wiemer, K Lewis, RJ Hohl
Bioorganic & medicinal chemistry 6 (6), 687-694, 1998
Differential effects of monoterpenes and lovastatin on RAS processing
RJ Hohl, K Lewis
Journal of Biological Chemistry 270 (29), 17508-17512, 1995
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L Wang, B Jia, DF Claxton, WC Ehmann, WB Rybka, S Mineishi, S Naik, ...
Oncoimmunology 7 (9), e1469594, 2018
Consequences of mevalonate depletion: differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB
SA Holstein, CL Wohlford-Lenane, RJ Hohl
Journal of Biological Chemistry 277 (12), 10678-10682, 2002
Synergistic interaction of lovastatin and paclitaxel in human cancer cells
SA Holstein, RJ Hohl
Molecular cancer therapeutics 1 (2), 141-149, 2001
Synthesis and biological activity of isoprenoid bisphosphonates
LW Shull, AJ Wiemer, RJ Hohl, DF Wiemer
Bioorganic & medicinal chemistry 14 (12), 4130-4136, 2006
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
E Messing, JR Gee, DR Saltzstein, KM Kim, A diSant'Agnese, J Kolesar, ...
Cancer prevention research 5 (4), 621-630, 2012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20